Call for postdoctoral researcher: tumour heterogeneity
- Date: 19.11.2019
- Location: Champalimaud Centre for the Unknown
- Employer: Champalimaud Foundation
- Job type: Full Time
- Position: Postdoctoral Positions
- Application start: 19.11.2019 Application ends: 19.12.2019
Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a highly motivated Postdoctoral Researcher to join our research team.
The available position will focus on identifying the cellular and molecular mechanisms leading to tumour heterogeneity cancers that arise upon the constitutive activation of the Hedgehog signaling pathway. The position involves using state-of-the-art molecular tools in combination with genetic mouse models. The successful applicant will be integrated into the Sánchez-Danés research group at Champalimaud Research.
WORK TO BE PERFORMED
The Postdoctoral Researcher will study cellular heterogeneity within tumors aiming to elucidate the cellular and molecular mechanisms that contribute to tumor resistance and relapse after treatment.
This position will include a broad and evolving range of tasks, including:
~ Engineering and application of complex molecular and transgenic strategies.
~ Culture of mammalian cells in vitro.
~ Functional experiments in vivo and in vitro.
~ Bioimaging, including confocal microscopy.
~ Mouse genetic lineage tracing in different cancer models.
~ Co-preparation of grant proposals.
~ Assisting with the supervision of students.
PROFILE OF CANDIDATES
Any national, foreign and stateless candidate(s) holding a PhD degree in Life Sciences. Recognised (R2) Researcher profile according to the European Framework for Research Careers.
Essential skills and qualifications
~ PhD in Biology, Bioengineering, Biotechnology or similar.
~ Experience in the design and generation of complex molecular and transgenic strategies.
~ Expertise in virus production and mammalian cell culture.
~ Good capacity for team work, critical and communication skills.
~ Ability to work independently on a research project.
~ Fluency in English.
Additional optional skills and qualifications
~ Experience in any of the following areas will be beneficial to the application:
~ Knowledge of genetic mouse models.
~ Experience in preparing grant proposals.
~ Experience supervising students.
~ Full-time employment contract of unfixed term (expected minimum of 3 years).
~ Competitive remuneration package commensurate with skills, qualifications and experience (minimum salary in line with Horizon 2020 MSCA guidelines).
~ Full immersion into a research excellence ecosystem with highly motivated researchers, supported by state-of-the-art technology.
~ Continuous development opportunities.
This appointment will be funded in the first instance through QuantOCancer project (European Union’s Horizon 2020 research and innovation programme grant agreement No 810653).
Research is at the heart of the Champalimaud Centre for the Unknown, a modern research and clinical facility situated on the waterfront in Lisbon, Portugal.
Champalimaud Research comprises a team of over 250 scientists from around the world with foci in neuroscience and cancer research. English is the official language of the Centre. Lisbon’s sunny Atlantic Mediterranean climate, vibrant culture and high quality of life make this a great place to live and work.
HOW TO APPLY
To apply, please send a pdf including i) Curriculum Vitae, ii) Motivation Letter stating your interests and iii) contact details for 2 referees email@example.com with “*SánchezDanésMolecularCancerNov2019*[your last name]” in the subject line. Please also include in the email where you heard about the vacancy.
If you do not wish that we contact current or past employers, please state so and explain the reasons in your letter of motivation.
Review of applications will begin immediately. The deadline for receipt of applications is 19th December 2019.
Once your application is submitted you will receive a non-automated confirmation email within 7 days. If you do not receive this email, please contact CF Research Careers at firstname.lastname@example.org
Expected starting date: February 2020 (negotiable).
EVALUATION AND SELECTION PROCESS
The selection process will be conducted in two stages, with an initial selection of the candidates based on the submitted applications, followed by on-site interviews (or through videoconference, if necessary) with short-listed candidates.
In the first stage, the candidate’s selection will consist of the evaluation of the scientific and curricular backgrounds of the candidates, to be weighted as follows:
Motivation letter: 40%; Curriculum Vitae: 60%.
In the second stage, candidates will be shortlisted and invited to take part in an interview. Referees will be contacted only at this stage.
The selection committee is composed of Adriana Sánchez-Danés (Chair) and Henrique Veiga-Fernandes (Member).
All applicants will be informed of the final outcome of the recruitment process.
NON-DISCRIMINATION AND EQUAL ACCESS POLICY
The Champalimaud Foundation actively promotes a policy of non-discrimination and equal access, so that no candidate can be privileged, benefited, harmed or deprived of any right, on basis of age, sex, sexual orientation, marital status, family status, economic situation, education, social origin or condition, genetic heritage, reduced working capacity, disability, chronic illness, nationality, race, territory of origin, language, religion, political or ideological convictions, and trade union membership.
For any other enquiries, please send an email to email@example.com with “SánchezDanésMolecularCancerNov2019[your last name]” in the subject line.
(1) Sanchez-Danes, A.; Larsimont, J. C.; Liagre, M.; Munoz-Couselo, E.; Lapouge, G.; Brisebarre, A.; Dubois, C.; Suppa, M.; Sukumaran, V.; Del Marmol, V.; Tabernero, J.; Blanpain, C.,
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 2018, 562(7727):434-438.
(2) Debaugnies, M*.; Sanchez-Danes, A.*; Rorive, S.; Raphael, M.; Liagre, M.; Parent, M. A.; Brisebarre, A.; Salmon, I.; Blanpain, C.,
YAP and TAZ are essential for basal and squamous cell carcinoma initiation. EMBO Rep 2018, 19 (7). * denotes co-first authors
(3) Sanchez-Danes, A.; Blanpain, C.,
Deciphering the cells of origin of squamous cell carcinomas. Nat Rev Cancer 2018, 18 (9), 549-561.
(4) Sanchez-Danes, A*.; Hannezo, E.*; Larsimont, J. C.; Liagre, M.; Youssef, K. K.; Simons, B. D.; Blanpain, C.,
Defining the clonal dynamics leading to mouse skin tumour initiation. Nature 2016, 536 (7616), 298-303.